Genome‐wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer
Authors:
Open Access
- 16 July 2021
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 149 (9) , 1713-1722
Abstract
Chemotherapies administered at normal therapeutic dosages can cause significant side‐effects and may result in early treatment discontinuation. Inter‐individual variation in toxicity highlights the need for biomarkers to personalise treatment. We sought to identify such biomarkers by conducting 40 genome‐wide association studies, together with gene and gene set analyses, for any toxicity and 10 individual toxicities in 1800 patients with advanced colorectal cancer treated with oxaliplatin and fluoropyrimidine chemotherapy ± cetuximab from the MRC COIN and COIN‐B trials (385 patients received FOLFOX, 360 FOLFOX + cetuximab, 707 XELOX and 348 XELOX + cetuximab). Single nucleotide polymorphisms (SNPs), genes and gene sets that reached genome‐wide or suggestive significance were validated in independent patient groups. We found that MROH5 was significantly associated with neutropenia in MAGMA gene analyses in patients treated with XELOX (P = 6.6 × 10−7) and was independently validated in those receiving XELOX + cetuximab; pooled P = 3.7 × 10−7. rs13260246 at 8q21.13 was significantly associated with vomiting in patients treated with XELOX (odds ratio = 5.0, 95% confidence interval = 3.0‐8.3, P = 9.8 × 10−10) but was not independently replicated. SNPs at 139 loci had suggestive associations for toxicities and lead SNPs at five of these were independently validated (rs6030266 with diarrhoea, rs1546161 with hand‐foot syndrome, rs9601722 with neutropenia, rs13413764 with lethargy and rs4600090 with nausea; all with pooled P's < 5.0 × 10−6). In conclusion, the association of MROH5 with neutropenia and five other putative biomarkers warrant further investigation for their potential clinical utility. Despite our comprehensive genome‐wide analyses of large, well‐characterised, clinical trials, we found a lack of common variants with modest effect sizes associated with toxicities.Keywords
Funding Information
- Cancer Research UK (C1298/A8362)
This publication has 43 references indexed in Scilit:
- Targeted Deletion of the Metastasis-Associated Phosphatase Ptp4a3 (PRL-3) Suppresses Murine Colon CancerPLOS ONE, 2013
- Targeted Disruption of the BCL9/β-Catenin Complex Inhibits Oncogenic Wnt SignalingScience Translational Medicine, 2012
- Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancerGut, 2011
- Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialThe Lancet Oncology, 2011
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialThe Lancet, 2011
- Balancing the efficacy and toxicity of chemotherapy in colorectal cancerTherapeutic Advances in Medical Oncology, 2010
- Recurrent nausea, vomiting and abdominal pain due to hypothyroidismBMJ Case Reports, 2010
- Deletion of the Chloride Transporter Slc26a7 Causes Distal Renal Tubular Acidosis and Impairs Gastric Acid SecretionJournal of Biological Chemistry, 2009
- A PTP4A3 Peptide PIMAP39 Modulates TNF-Alpha Levels and Endotoxic ShockJournal of Innate Immunity, 2009
- PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage AnalysesThe American Journal of Human Genetics, 2007